| P50 | author | Steven I. Sherman | Q43011758 |
| P2093 | author name string | Bryan R Haugen | |
| P2860 | cites work | Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population | Q58001136 |
| | Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland | Q67748977 |
| | Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells | Q73453103 |
| | Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas | Q73739021 |
| | Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma | Q77357530 |
| | Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy? | Q77899005 |
| | Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer | Q79819385 |
| | Targeting BRAFV600E in thyroid carcinoma: therapeutic implications | Q79961076 |
| | Global cancer statistics | Q22241238 |
| | The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner | Q24312194 |
| | Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer | Q24596266 |
| | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer | Q27851696 |
| | Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 |
| | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 |
| | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 |
| | Cancer statistics, 2012 | Q27860574 |
| | Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations | Q28249293 |
| | Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer | Q28262641 |
| | The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer | Q28262702 |
| | Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer | Q28366607 |
| | Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 |
| | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 |
| | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 |
| | Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information | Q31129437 |
| | Approach to the thyroid cancer patient with extracervical metastases. | Q33536959 |
| | Targeting protein prenylation for cancer therapy | Q33679239 |
| | The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors | Q33770769 |
| | Prognostic utility of BRAF mutation in papillary thyroid cancer | Q33771120 |
| | Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways | Q33801421 |
| | Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling | Q33839230 |
| | Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr | Q33990855 |
| | Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. | Q33995708 |
| | BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells | Q34011519 |
| | MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo | Q34109756 |
| | K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors | Q34427029 |
| | Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo | Q34606336 |
| | Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. | Q34608416 |
| | Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation | Q34714310 |
| | Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies | Q34758477 |
| | Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer | Q34776121 |
| | Motesanib diphosphate in progressive differentiated thyroid cancer. | Q34791480 |
| | Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. | Q35023367 |
| | Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer | Q35295368 |
| | Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation | Q35578577 |
| | Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasia | Q35596740 |
| | Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion | Q35669749 |
| | RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors | Q35721081 |
| | The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells | Q35744471 |
| | High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas | Q35823973 |
| | Cancer stem cells: impact, heterogeneity, and uncertainty | Q35857599 |
| | Multiple signaling pathways converge on beta-catenin in thyroid cancer | Q36200220 |
| | Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy | Q36278239 |
| | Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients | Q36393021 |
| | Fetal cell carcinogenesis of the thyroid: theory and practice | Q36434198 |
| | The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. | Q36508942 |
| | Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 |
| | BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines | Q36732681 |
| | Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer | Q36788057 |
| | Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. | Q36836677 |
| | Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study | Q36877022 |
| | Chemical genetic discovery of targets and anti-targets for cancer polypharmacology | Q36988960 |
| | RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors | Q37048053 |
| | Bone metastases from differentiated thyroid carcinoma. | Q37098297 |
| | Phase II trial of sorafenib in advanced thyroid cancer | Q37121708 |
| | NCCN Task Force Report: Oral chemotherapy. | Q37123847 |
| | Phase II trial of sorafenib in metastatic thyroid cancer | Q37158278 |
| | Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma | Q37165411 |
| | Molecular pathology of thyroid cancer: diagnostic and clinical implications | Q37337504 |
| | Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer | Q37379562 |
| | Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements | Q37505185 |
| | Ras signaling and therapies | Q37548931 |
| | Cytotoxic chemotherapy for differentiated thyroid carcinoma. | Q37746327 |
| | Targeted therapies for thyroid tumors. | Q37860132 |
| | Approach to the patient with advanced differentiated thyroid cancer. | Q37926291 |
| | The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? | Q37945533 |
| | Small molecule inhibitors of BRAF in clinical trials | Q37973551 |
| | Update in utility of secondary node dissection for papillary thyroid cancer | Q38026026 |
| | Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma | Q38430741 |
| | Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. | Q39412894 |
| | Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation | Q39421033 |
| | RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models | Q39692674 |
| | Gatekeeper mutations mediate resistance to BRAF-targeted therapies. | Q39694616 |
| | Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations | Q40073236 |
| | Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. | Q40079043 |
| | Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 |
| | Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo | Q40301455 |
| | Mutation of the PIK3CA gene in anaplastic thyroid cancer. | Q40351486 |
| | Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells | Q40427760 |
| | Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity | Q42775676 |
| | Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q43016588 |
| | Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. | Q43251079 |
| | Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. | Q43272859 |
| | Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers | Q46585245 |
| | Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 |
| | A phase II study of gefitinib in patients with advanced thyroid cancer. | Q46912384 |
| | Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial | Q47255118 |
| | Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. | Q50778135 |
| | Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma | Q51744485 |
| | Tumorigenic and metastatic activity of human thyroid cancer stem cells. | Q53294256 |
| | Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. | Q53361697 |
| | E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. | Q53780532 |
| | Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. | Q54323561 |
| | A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. | Q54420344 |
| P433 | issue | 3 | |
| P921 | main subject | differentiated thyroid carcinoma | Q56013722 |
| P304 | page(s) | 439-455 | |
| P577 | publication date | 2013-04-10 | |
| P1433 | published in | Endocrine Reviews | Q3054007 |
| P1476 | title | Evolving approaches to patients with advanced differentiated thyroid cancer | |
| P478 | volume | 34 | |